UK ‘Octopus’ trial tackling multiple sclerosis is a world first
A ground breaking mega-trial for progressive multiple sclerosis will be launched in the UK later this year.
Octopus, so called because of its multiple arms, is a revolutionary clinical trial that will transform the way...
Pioneering technique paves way for fast and cheap fabrication of rapid medical diagnostic tools
Breakthrough promises to democratise microfluidics and lab-on-a-chip technology, benefiting resource-poor countries and settings.
New technology developed by the University of Bristol has the potential to accelerate uptake and development of on-chip diagnostic techniques in parts...
CRYONISS EARNS COVETED MHRA QUALITY MARK
Experts in biological sample, and medicinal product, storage and logistics management, CRYONISS offers a comprehensive storage service from ambient down to vapour phase liquid nitrogen.
The Cheshire-based team has a wealth of experience in supporting...
Automated drug discovery platform brings about paradigm change for research
Bringing a single new drug to market takes years of research and costs billions – with the COVID-19 pandemic highlighting even more how critical it is to accelerate this process. The high costs and...
Clinical trials for gene and cell therapies
In early 2020, the Cell and Gene Therapy Catapult (CGTC) reported that there were 127 ongoing trials in advanced therapy medicinal products (ATMP) in the UK. This represented 12 percent of trials globally, helping...
WEAPONISING THE FIGHT AGAINST ANTIBIOTIC RESISTANCE
Could faecal transplants be an effective weapon in the fight back against antibiotic resistance? A research team at Guy’s and St Thomas’ NHS Foundation Trust intends to find out, once and for all.
By HELEN...
How a Novel Drug Discovery Technology Could Help in the Fight Against COVID-19
By Dr Asif Tulah, Alcyomics
Alcyomics has been adapting its service provision and assays to play their part in the race to find new treatments for COVID-19 (SARS-CoV-2) and to better understand how this virus works....
IBM releases novel AI-powered technology to accelerate medical research for COVID-19
IBM has today released a new set of cloud- and AI-powered technologies to help researchers, doctors and scientists accelerate COVID-19 drug discovery.
These novel resources, from across IBM and available beginning today (Friday 3 April)...
Diagnostic devices reimagined
Diagnostic devices are coming on in leaps and bounds but you may be surprised to learn that one device that’s remained much the same since the late 1950s is the colonoscope. One researcher working...
Relentlessly searching for the cure
Martina Slapkova - Research Information Co-ordinator at the Motor Neurone Disease Association
Motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis across the globe, has been puzzling researchers and clinicians ever since it was...
Matching clinical trials with unmet clinical need
A new tool that helps target clinical trials to areas of unmet clinical need has sparked interest in both the National Health Service (NHS) and the commercial clinical research world. Stephen Lock, Head of...
Making clinical trials right for older people
In this issue, we speak to Miles Witham, Professor of Trials for Older People at Newcastle University and consultant geriatrician, about why he’s bringing about a sea change in how clinical trials involving older...
Bringing patients and providers together one tweet at a time
As an open forum for human interaction, social media have become the great equalizer of health information – providing a means for patients and health care providers to connect outside of the hospital or...
Adult Vaccination
“Vaccination can provide cost-effective protection against a host of diseases throughout life, but remains an underused public-health strategy in adults for the promotion of healthy ageing. Without specific vaccination programmes for the adult population...
Stay future-ready: Running parallel operations with a CDMO during clinical trials
Bringing a drug candidate through clinical trials is a challenging and high-risk process, since only 10% of candidates actually reach final approval. Both established pharma companies and small startups are often faced with this...